The QualityStocks Daily Thursday, October 6th, 2022

Today's Top 3 Investment Newsletters

The Stock Dork(GGE) $1.8800 +168.57%

QualityStocks(NVIV) $7.9800 +83.03%

MarketClub Analysis(BEAT) $5.7300 +26.49%

The QualityStocks Daily Stock List

Tilray (TLRY)

InvestorPlace, Schaeffer's, The Street, StocksEarning, MarketBeat, MarketClub Analysis, Trades Of The Day, QualityStocks, Daily Trade Alert, StockMarketWatch, StreetInsider, Kiplinger Today, Wealth Insider Alert, The Online Investor, Market Intelligence Center Alert, BUYINS.NET, Zacks, Investopedia, CFN Media Group, CNBC Breaking News, Daily Profit, StreetAuthority Daily, The Street Report, StockEarnings, INO Market Report, Trading For Keeps, InvestmentHouse, Trading Concepts, The Rich Investor, Top Pros' Top Picks, Inside Trading, Eagle Financial Publications, Early Bird, Investment House, InvestorsObserver Team, Investors Alley, InvestorsUnderground, Jason Bond, Jim Cramer, Louis Navellier, Marketbeat.com, Outsider Club, Rick Saddler, Stock Up Featured, StrategicTechInvestor, TheTradingReport, Tip.us, VectorVest, Wealth Daily, wyatt research newsletter and Money Morning reported earlier on Tilray (TLRY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tilray, Inc. (NASDAQ: TLRY) is a pharmaceutical firm that is engaged in research, growing, production and distribution of cannabinoids, recreational and medical marijuana. The firm operates through its Hemp and Cannabis Segments.

The firm’s Hemp segment sales are made up of broad spectrum hemp extract that contains CBD, hemp food and hemp seed, which are sold directly to consumers, or to wholesalers and retailers, in unlicensed operations. On the other hand, its Cannabis segment sales are made up of medical, adult-use and huge sales of marijuana under regulated licenses, which are sold directly to patients as well as to governments, pharmacies, wholesalers and retailers. The firm also provides its products to researchers for commercial purposes, as well as for clinical research applications and compassionate access.

Tilray was founded on January 24 in 2018 and is based in Nanaimo, Canada. The firm operates in other countries apart from Canada, including the United Kingdom, Argentina, the U.S., Australia, Switzerland, Chile, South Africa, Portugal, Croatia, New Zealand, Cyprus, Ireland, the Czech Republic, Israel and Germany.

Tilray develops marijuana based medicines, drops, dried marijuana and marijuana extracts, as well as oil products. The firm sells these products through various brands under it, including Manitoba Harvest, Dubon and Canaca. The firm’s subsidiary - FHF Holdings Ltd, also markets, manufactures and distributes consumer products that are hemp-based. Apart from a partnership with AB InBev to develop marijuana-infused drinks, the company recently announced that it would be merging with Aphria Inc., another Canadian cannabis firm.

Many anticipate that this merger may broaden both companies’ hold on the cannabis market, as this merger may make them one of the largest firms globally. Their combined range, from Tilray’s Portugal facility to Aphria’s CC Pharma asset in Germany, may also provide both firms with a competitive edge in the budding marijuana market.

Tilray (TLRY), closed Thursday's trading session at $3.9, up 30.8725%, on 103,359,356 volume. The average volume for the last 3 months is 1.555M and the stock's 52-week low/high is $2.65/$13.95.

InVivo Therapeutics (NVIV)

QualityStocks, OurHotStockPicks, Xtremepicks, Real Pennies, TraderPower, TheStockAdvisor, StockMarketWatch, BullRally, BUYINS.NET, CoolPennyStocks, HotOTC, MadPennyStocks, PennyInvest, PennyStockVille, SmallCapVoice, StockRich, StockEgg, MarketBeat, SmallCap Fortunes, TheMicrocapNews, OTC Stock Review, Marketbeat.com, M2 Communications, InvestorPlace, InvestmentHouse, TheStockAdvisors, Top Pros' Top Picks, Buzz Stocks, TopPennyStockMovers, Weekly Wizards, INO Market Report, PennyTrader Publisher, NYC Marketing Inc, Stock Market Watch, OTCtipReporter, The Street, Streetwise Reports, PennyStockScholar, Barchart, StockOodles, Schaeffer's, SECFilings.com News, StockEarnings and MarketClub Analysis reported earlier on InVivo Therapeutics (NVIV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) (FRA: 04IC) is a clinical-stage research and biotechnology firm that is focused on the development and commercialization of biopolymer scaffolding devices which are used to treat spinal cord injuries.

The firm is based in Cambridge, Massachusetts and was incorporated in January 2005 by Robert Langer, Frank M. Reynolds and Joseph P. Vacanti. It operates in the healthcare sector, under the medical equipment and devices sub-industry.

The company’s objective is to change the treatment of spinal cord injuries by modulating the healing environment to facilitate cell growth and survival. Currently, it is focused on using polymers as a platform technology to develop therapies that will enhance function in patients who experienced traumatic spinal cord injuries and got paralyzed as a result.

The enterprise’s pipeline comprises of an investigational bio-resorbable polymer scaffold developed for implantation at the injured site in a spinal cord, known as a Neuro-Spinal Scaffold implant. The scaffold has been designed to encourage functional cells to fill in the cavity that develops at the injury site in a spinal cord. Its success has the potential to improve motor and sensory function, leading to a better quality of life for patients.

The U.S. FDA recently announced its acceptance of the firm’s preclinical module, which brings them one step closer to complete HDE submission. The firm is now enrolling acute spinal cord injury patients into its INSPIRE 2 study which has been designed to expand upon clinical evidence of its spinal scaffold implant from its INSPIRE 1 study. Final approval from the FDA for its neuro-spinal scaffold implant will not only allow the company to help patients with spinal cord injuries but also bring in more investments into the firm, which will boost the company’s growth.

InVivo Therapeutics (NVIV), closed Thursday's trading session at $7.98, up 83.0275%, on 1,555,095 volume. The average volume for the last 3 months is 1.32M and the stock's 52-week low/high is $3.50/$16.50.

BioSig Technologies (BSGM)

Broad Street, QualityStocks, AwesomeStocks, StockWireNews, Small Cap Firm, MarketBeat, Fierce Analyst, Stock Commander, StockStreetWire, BUYINS.NET, OTCBB Journal, SeeThruEquity Research, MarketClub Analysis, StockMarketWatch, WallstreetSurfers, StocksEarning, Penny Stocks Finder, PennyStock Tweets, SizzlingStockPicks, Stockgoodies, Wolf of Penny Stocks, Penny Picks, Penny Stock Craze, Winston Small Cap, Beacon Equity Research, The Wall Street Transcript, SuperStockTips, Make Penny Stocks Great Again, Leading Penny Stocks, PennyStockLocks.com, InvestorSoup, StockRockandRoll, StockHideout, Epic Stock Picks, Stock Preacher, Damn Good Penny Picks, DreamTeamNetwork, Goldman Small Cap Research, Mega Stock Alerts, BuzzStocks, Pumps and Dumps, Wall Street Resources, TradersPro, Street Picks, StocksImpossible, Stock News Now, Shiznit Stocks, PennyStockProphet, ResearchOTC, OTCtipReporter, Profitable Trader Authority, PennyStockScholar, PennyStockLocks, Penny Stock General, Penny Stock Finder, Penny Stock 101, Penny Pick Finders and SECFilings.com News reported earlier on BioSig Technologies (BSGM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BioSig Technologies Inc. (NASDAQ: BSGM) is a medical device firm that is focused on the development and commercialization of medical devices, with a focus on its biomedical signal processing platform.

The firm has its headquarters in Westport, Connecticut and was incorporated in 2009, on February 24th by Kenneth L. Londoner. It serves consumers in the United States.

The company is party to a strategic collaboration agreement with the Mayo Foundation for Medical Education and Research, which entails the development of a machine learning and AI software solution for its real-time electrogram electrophysiology PURE EP systems. It is also party to a research agreement with the University of Minnesota, which entails the development of new therapies for the treatment of sympathetic nervous system illnesses.

The enterprise’s products includes its signal processing platform known as the PURE EP system, which combines software and hardware to address challenges linked to signal acquisition. The precise uninterrupted real-time platform is a computerized system that has been designed to acquire, digitize, filter, calculate, display, record and store intracardiac and electrocardiographic signals for individuals who are undergoing electrophysiology procedures. The platform allows electrophysiologists to observe signals and analyze them immediately. The enterprise is also focused on improving intracardiac signal acquisition and diagnostic information for the procedures of ventricular tachycardia and atrial fibrillation.

The firm recently released its PURE EP system clinical data, which show a 75% overall improvement in intracardiac signal quality. Its CEO noted that the results validated the clinical importance of the firm’s technology as well as the firm’s position for continued growth and success. The firm is focused on advancing the field of electrophysiology and bioelectronics medicine.

BioSig Technologies (BSGM), closed Thursday's trading session at $0.88, up 28.8056%, on 1,327,850 volume. The average volume for the last 3 months is 8.409M and the stock's 52-week low/high is $0.50/$4.1007.

Green Giant (GGE)

QualityStocks reported earlier on Green Giant (GGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Green Giant Inc. (NASDAQ: GGE) is a real estate developer firm that is focused on the development of real estate properties.

The firm has its headquarters in Hanzhong, China and was incorporated in 1995 by Xiao Jun Zhu. Prior to its name change in March 2022, the firm was known as China HGS Real Estate Inc. It operates as part of the real estate development industry, under the real estate sector. The firm serves consumers in the People’s Republic of China.

The company is focused on developing sub-high-rise and high-rise multi-building apartment complexes and residential buildings in the Tier 3 and Tier 4 cities and counties in China which have populations that are growing rapidly as a result of increased urbanization. Its objective is to offer affordable housing with modern designs that can meet the needs of various buyer groups. The majority of the company’s revenue is derived from the sale of commercial properties and condominiums.

The enterprise constructs and sells residential apartments, commercial properties and parking lots. It also develops apartment buildings as well as office buildings and provides a range of services, including sales and marketing, design and construction management, project planning, land acquisition and property management. This is in addition to offering pre-sale and after sale services.

The firm remains focused on aligning its business with its corporate strategy as it continues to evolve in the market. This will help create value for its shareholders while also encouraging more investments into the firm, which will be good for its growth.

Green Giant (GGE), closed Thursday's trading session at $1.88, up 168.5714%, on 8,408,890 volume. The average volume for the last 3 months is 1.777M and the stock's 52-week low/high is $0.66/$3.80.

IonQ Inc. (IONQ)

MarketClub Analysis, Schaeffer's, InvestorPlace, Trades Of The Day, The Online Investor, FreeRealTime and Daily Trade Alert reported earlier on IonQ Inc. (IONQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

IonQ Inc. (NYSE: IONQ) is a computing hardware and software firm that is focused on developing general-purpose quantum computing systems.

The firm has its headquarters in College Park, Maryland and was incorporated in 2015. It operates as part of the computer hardware industry, under the technology sector. The firm serves consumers across the globe.

The company’s mission is to build the best quantum computers in the world, which can solve the most complex problems. It hopes to realize the world-changing potential of quantum computing. The company has a track record of innovation and deployment.

The enterprise develops a general-purpose trapped ion quantum computer and software to optimize, generate and execute quantum circuits. Its computer systems comprise of trapped-ion quantum technology. The enterprise provides access to a quantum computer with 20 qubits, which is said to be the most powerful trapped-ion quantum computer. It enables consumers to use the quantum computing systems via a quantum computing-as-a-service (QCaaS) platform. The enterprise is the only firm with its quantum systems available through the cloud on Amazon Braket, Google Cloud and Microsoft Azure, as well as through direct API access. It mainly serves academic and commercial institutions.

The firm recently secured a contract to provide quantum solutions to the U.S. Airforce research laboratory. This move will not only maintain the firm’s competitive advantage and accelerate various quantum technology projects, but also bring in additional revenues and investments into the firm, which will be good for its growth.

IonQ Inc. (IONQ), closed Thursday's trading session at $5.64, off by 1.2259%, on 1,822,354 volume. The average volume for the last 3 months is 843,673 and the stock's 52-week low/high is $4.16/$35.90.

Hyliion Holdings (HYLN)

InvestorPlace, StocksEarning, MarketBeat, The Online Investor, Schaeffer's, Daily Trade Alert, Trades Of The Day, Early Bird and Daily Stocks reported earlier on Hyliion Holdings (HYLN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hyliion Holdings Corp (NYSE: HYLN) is a company that is engaged in the provision of electrified powertrain solutions for the commercial vehicle industry.

The firm has its headquarters in Cedar Park, Texas and was incorporated in 2015 by Thomas Healy. It operates as part of the auto parts industry, under the consumer cyclical sector. The firm serves consumers around the globe.

The company is mainly focused on the reduction of carbon intensity and greenhouse gas emissions of commercial transportation vehicles. Its vehicles have been designed to lower the total cost of ownership and improve performance, while leveraging the existing alternative fuel infrastructure.

The enterprise uses its battery systems, control software and data analytics, combined with fully integrated electric motors and power electronics to produce electrified powertrain systems. It provides 2 different product lines; the Hypertruck ERX system, which is a complete powertrain option that has a fully electric drive and uses an onboard generator to recharge the batteries as the vehicle is in operation; and the Hybrid system, which is designed to be an add-on to the electric powertrain of trucks can augment power needs. The enterprise also offers battery management systems for fully electric and hybrid vehicle applications.

The firm recently acquired KARNO, a hydrogen and fuel agnostic capable generator from GE Additive. This furthers its mission to reduce emissions and will positively influence revenues and investments into the firm while also opening the firm up to new growth opportunities.

Hyliion Holdings (HYLN), closed Thursday's trading session at $2.77, off by 3.1469%, on 860,897 volume. The average volume for the last 3 months is 64,140 and the stock's 52-week low/high is $2.69/$9.12.

Fresh Tracks Therapeutics (FRTX)

We reported earlier on Fresh Tracks Therapeutics (FRTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fresh Tracks Therapeutics Inc. (NASDAQ: FRTX) (FRA: VCC) is a clinical-stage pharmaceutical firm that is focused on developing a range of prescription therapeutics for the treatment of inflammatory, autoimmune and other debilitating illnesses.

The firm has its headquarters in Boulder, Colorado and was incorporated in 2009 by Andrew D. Sklawer and Reginald L. Hardy. Prior to its name change in September 2022, the firm was known as Brickell Biotech Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the world, with a focus on those in the United States.

The company’s primary focus is to transform the lives of patients by developing ground-breaking and innovative prescription therapeutics. It is party to license and collaboration agreements with AnGes Inc., Dr. Nicholas S. Bodor, Bodor Laboratories Inc., Voronoi Inc. and Carna Biosciences Inc.

The enterprise’s product pipeline is comprised of a covalent stimulator of interferon genes inhibitor known as BBI-10, for the potential treatment of rare genetic and auto-inflammatory illnesses; an oral DYRK1A inhibitor dubbed BBI-02for the treatment of inflammatory and autoimmune illnesses; and sofpironium bromide, which has completed Phase 3 trials evaluating its effectiveness in treating primary auxiliary hyperhidrosis.

The firm, which recently rebranded and established a scientific advisory board, remains focused on its mission to develop new therapies that restore immune balance. The success and approval of its therapies will not only benefit patients with a range of indications but also significantly bolster its overall growth.

Fresh Tracks Therapeutics (FRTX), closed Thursday's trading session at $1.97, off by 3.9024%, on 64,140 volume. The average volume for the last 3 months is 79,776 and the stock's 52-week low/high is $1.67/$34.155.

Novonix Limited (NVNXF)

TradersPro reported earlier on Novonix Limited (NVNXF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Novonix Limited (OTCQX: NVNXF) (ASX: NVX) (FRA: GC3) is an integrated developer and supplier of materials, equipment and services for the global lithium-ion battery industry.

The firm has its headquarters in Brisbane, Australia and was incorporated in April 2012 by Gregory Alexander John Baynton. Prior to its name change in July 2017, the firm was known as Graphitecorp Ltd. It operates as part of the electrical equipment and parts industry, under the industrials sector. The firm serves consumers around the globe, with a focus on North America.

The company’s mission is to enable a clean energy future through the production of longer-life and lower-cost battery materials and technologies. It operates through the Battery materials, Battery technology and Graphite exploration and mining segments.

The materials segment is involved in the development and manufacture of battery anode materials, while the technology segment carries out research and development in battery development and develops battery cell testing equipment. On the other hand, the exploration and mining segment explores for and develops high-grade flake graphite deposits. All segment activities relating to Graphite Exploration and Mining are carried out in Australia while battery technology and materials activities are carried out in North America.

The enterprise has developed a new environmentally-friendly process to produce graphite anode material for Li-ion batteries. It is also involved in investment and battery testing activities.

The company, which is leading in environmentally sustainable manufacturing practices in the industry, remains focused on advancing its strategy to develop a U.S.-based Li-ion battery materials supply chain. This will significantly increase revenues and help extend its consumer reach, which will, in turn, help create shareholder value.

Novonix Limited (NVNXF), closed Thursday's trading session at $1.24, off by 0.8%, on 79,776 volume. The average volume for the last 3 months is 19,052 and the stock's 52-week low/high is $1.06/$8.90.

Wag! Group (PET)

Stockhouse, QualityStocks, MarketBeat and Energy and Capital reported earlier on Wag! Group (PET), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Wag! Group Co. (NASDAQ: PET) is a pet services marketplace firm that is focused on the development and support of a proprietary marketplace technology platform available as a mobile application and website, which allows independent pet caregivers to connect with pet parents.

The firm has its headquarters in Purchase, New York and was incorporated in 2015. Prior to its name change, the firm was known as CHW Acquisition Corp. It operates as part of the software-application industry, under the technology sector. The firm serves consumers in the United States.

The company is focused on becoming the number one platform for busy pet parents, through the provision of 5-star pet sitting, dog walking, wellness plans, one-on-one training and expert pet advice. It prioritizes safety and wellness, in addition to empowering pet caregivers to care for pets in their neighborhoods and earn real money.

The enterprise’s app facilitates on-demand hiring for dog sitting, dog walking and dog boarding services. It also features GPS tracking and pup reports, allowing dog owners to track their dogs easily and receive a report card indicating the route walked, time taken and distance traveled. This is in addition to providing insurance plans for pets and wellness plans that cover flea and tick, meds and vaccines.

The company recently announced its latest financial results, which show exceptional revenue growth. Its CEO noted that they remained focused on advancing their growth strategy, which will, in turn, boost the company’s profitability and help deliver long-term shareholder value.

Wag! Group (PET), closed Thursday's trading session at $2.42, off by 0.411523%, on 19,052 volume. The average volume for the last 3 months is 16.076M and the stock's 52-week low/high is $1.96/$13.13.

Marathon Digital Holdings Inc. (MARA)

InvestorPlace, MarketClub Analysis, Schaeffer's, StockMarketWatch, QualityStocks, MarketBeat, TradersPro, StocksEarning, Lebed.biz, BUYINS.NET, The Online Investor, Trades Of The Day, The Street, Daily Trade Alert, TraderPower, Marketbeat.com, PoliticsAndMyPortfolio, TopPennyStockMovers, Wall Street Mover, FeedBlitz, Kiplinger Today, Wealth Insider Alert, StreetAuthority Daily, InvestorsUnderground, Barchart, DreamTeamNetwork, RedChip, AllPennyStocks, Stock Analyzer, Stock Beast, StockOodles, Street Insider, StreetInsider and Promotion Stock Secrets reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Marathon Digital Holdings (NASDAQ: MARA), a leader in supporting and securing the Bitcoin ecosystem, has released unaudited Bitcoin (“BTC”) production and miner installation updates for September 2022. According to the announcement, Marathon produced 360 BTC in September 2022, with a total of 616 BTC in Q3 2022. In addition, the company noted that total Bitcoin Holdings reached 10,670 BTC, which represents a fair market value of $207.3 million. Looking forward, the company observed that current operations at its King Mountain wind farm are in line with expectations. The announcement also noted that the King Mountain facility is hosted by Compute North, which recently initiated Chapter 11 bankruptcy proceedings. Marathon stated that the bankruptcy proceedings, which are aimed at stabilizing Compute North, should not impact MARA’s current operations or its ability to achieve its primary target of 23 exahashes per second in 2023. “During the third quarter, we sequentially improved our Bitcoin production as we successfully transitioned out of our facility in Montana and continued scaling operations at new locations, including the King Mountain wind farm in Texas,” said Marathon chair and CEO Fred Thiel in the press release. “This progress has continued into the first week of October with approximately 19,000 additional miners, representing approximately 2.0 exahashes per second, coming online since the quarter’s end. As of today, Marathon’s active fleet currently consists of approximately 57,000 active miners, representing approximately 5.7 exahashes per second. We expect to continue building our hash rate in the fourth quarter as approximately 19,000 additional miners, representing approximately 2.0 exahashes per second, are expected to come online in the next 30 days.”

To view the full press release, visit https://ibn.fm/57xno

About Marathon Digital Holdings Inc.

Marathon is a digital asset technology company that focuses on supporting and securing the Bitcoin ecosystem. The company is currently in the process of becoming one of the largest and most sustainably powered Bitcoin mining operations in North America, while remaining asset light. For more information about the company, please visit www.MarathonDH.com.

Marathon Digital Holdings Inc. (MARA), closed Thursday's trading session at $13.1, up 2.0249%, on 16,076,234 volume. The average volume for the last 3 months is 434,990 and the stock's 52-week low/high is $5.20/$83.45.

Royal Gold Inc. (RGLD)

TopStockAnalysts, Streetwise Reports, StreetAuthority Daily, InvestorPlace, TradingAuthority Daily, The Street, MarketBeat, Daily Wealth, Top Pros' Top Picks, StreetInsider, Daily Trade Alert, SmarTrend Newsletters, TheStockAdvisor, All about trends, Energy and Capital, Zacks, Money Morning, QualityStocks, MarketClub Analysis, The Growth Stock Wire, TheStockAdvisors, Trades Of The Day, Dividend Opportunities, Marketbeat.com, Wyatt Investment Research, Barchart, Wealth Daily, Uncommon Wisdom, Lebed.biz, Investor Update, Daily Profit, Schaeffer's, Investment U, Money and Markets, National Inflation Association, Stockhouse, The Online Investor, Traders For Cash Flow, TradingMarkets, Greenbackers, Forbes, Outsider Club, Kiplinger Today, Trade of the Week, Weekly Wizards, Market Intelligence Center Alert, Inside Investing Daily, Bourbon and Bayonets, BestChartNow, Wealth Insider Alert, AllPennyStocks, FNNO Newsletters, ChartAdvisor, GorillaTrades, Dynamic Wealth Report, One Hot Stock, INO.com Market Report, Investing Futures, The Best Newsletters, Investopedia, StocksEarning, Stocks That Move, Market Authority, Market FN, Stansberry Research, Short Term Wealth, Profits Run, PowerRatings Stocks, Penny Stock Chaser and Hit and Run Candle Sticks reported earlier on Royal Gold Inc. (RGLD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

During times of economic upheaval, investors have traditionally stored their wealth in assets such as gold. Since gold is especially resistant to economic downturns, the metal acts as a great store of value and is often in high demand when investors foresee inflation or recession.

With the global economy taking a battering in recent years due to the coronavirus pandemic and the Russia-Ukraine war, most financial experts are predicting that economic conditions will deteriorate worldwide. Actions by the U.S. Fed and central banks around the world to combat inflation have only increased fears of a recession among most pundits.

In such a pessimistic atmosphere, assets such as gold should be selling like hotcakes as investors scramble to protect the value of their assets from deteriorating. However, gold has performed poorer than expected in recent months, with spot gold dropping by 7.4% this year amid increasing government bond yields and a surging greenback.

Given gold’s poor performance, many investors are probably wondering if the precious metal will continue to act as a store of value.

Quoting a recent report, Kitco’s gold columnist Jim Wyckoff noted that traders have been ramping up their gold short positions. He also said that fund managers have been more bearish on gold than they have been in the past four years.

Even so, Michael Maharrey writes that despite gold’s relatively poor performance, it is still the best-performing asset of the year. The metal outperformed foreign bonds, U.S. bonds, foreign stocks, the S&P 500, the UN Treasury Inflation-Protected Securities (TIPS) and the NASDAQ, he wrote, noting that the U.S. dollar and commodities such as agricultural goods are the only ones that managed to outperform gold.

Maharrey noted that while gold prices have dropped by more than 30% in 2022, they haven’t fallen as far as other assets. Furthermore, he stated that having gold in your portfolio may have helped to shield investors against losses in other asset classes.

The dollar, for instance, may have seen a historic rise in value, but high inflation means that the greenback, despite surging against other currencies, has been devalued. Schiffgold reported back in June that the average American household would have to spend around $5,200 more than they did last year for the same needs.

A model from the World Gold Council shows that gold prices should have gone down by around 30% due to the surging dollar and increasing interest rates. The precious metal didn’t fall that far, however. Demand for gold among central banks remains strong, and pundits predict that investors may turn to high-liquidity assets such as gold as geopolitical and recessionary risks increase.

Investors have to do their due diligence and decide whether they would prefer to invest in gold extraction companies such as Royal Gold Inc. (NASDAQ: RGLD) or put their money in physical gold and other such vehicles.

Royal Gold Inc. (RGLD), closed Thursday's trading session at $99.43, up 1.9899%, on 435,720 volume. The average volume for the last 3 months is 66.725M and the stock's 52-week low/high is $84.54/$147.70.

NIO Inc. (NIO)

Green Car Stocks, InvestorPlace, Schaeffer's, The Street, MarketClub Analysis, MarketBeat, Daily Trade Alert, Trades Of The Day, StocksEarning, Kiplinger Today, The Online Investor, StreetInsider, Zacks, QualityStocks, StockMarketWatch, INO Market Report, BUYINS.NET, Cabot Wealth, Wealth Insider Alert, The Wealth Report, CNBC Breaking News, Early Bird, InvestorsUnderground, Investopedia, Daily Wealth, TradersPro, wyatt research newsletter, Energy and Capital, Investors Alley, CRWEWallStreet, FreeRealTime, Jim Cramer, Wealth Daily, InvestorsObserver Team, AllPennyStocks, MarketClub, TopPennyStockMovers, Top Pros' Top Picks, Stock Market Watch and InvestorIntel reported earlier on NIO Inc. (NIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Most major automakers have committed to electrifying their vehicle lineups over the next couple of decades. Established car companies such as Ford and Hyundai have already begun producing electric cars for the mass market, and those that haven’t produced an EV have pledged to unveil electric models in the coming years. However, one major automaker has held back from making any electric vehicle amid increasing criticism from various sectors.

Toyota, which popularized the hybrid powertrain with the Toyota Prius Hybrid, has no set strategy for battery electric vehicles. Instead, the Japanese automaker seems to have put all its hopes on hydrogen fuel cell cars. The Toyota Mirai is one of the only fuel cell cars on the market right now, and Toyota has indicated that it intends on investing in hydrogen fuel cell technology in the near future.

Last Thursday, Toyota CEO Akio Toyoda said that the company planned on pushing forward with its fuel cell EV strategy and will soon unveil a lineup of electrified vehicles that run on liquid hydrogen and traditional rechargeable lithium-ion battery packs. Over the coming years, the Japanese automaker will invest nearly $70 billion in electrified cars, with $35 billion being invested in all-electric models over nine years.

This announcement comes amid criticism from investors and environmental groups which felt that Toyota was transitioning to battery electric vehicles (BEVs) too slowly. Unlike other automakers that have embraced BEVs, Toyota, with Akio Toyoda at the helm, has adopted a carbon emissions strategy that isn’t centered around battery-powered electric cars. The automaker plans to have produced 3.5 million EVs by 2030 and that would only make one-third of its total car sales.

Comparatively, other automakers plan on completely phasing out the combustion engine and exclusively selling battery electric cars over the next two decades. And even though the hybrid Toyota Prius is still one of the most fuel-efficient, gas-powered cars on the market, critics can’t get over the fact that hybrids still use combustion engines. Sierra Club’s Clean Transportation for All Campaign director Katherine Garcia argued in a recent blog post that hybrids are not green because they run on carbon-emitting combustion engines.

In a recent study of 10 carmakers’ efforts to decarbonize their production lines, Greenpeace ranked the Japanese automaker last, stating that its sales of zero-emission cars made up less than 1% of its total vehicle sales. Even so, Toyota is keen on following its strategy of providing a wide array of electrified vehicles, not just battery electric cars.

Should Toyota later change its strategy in favor of fully electric vehicles, it is likely to find startups such as NIO Inc. (NYSE: NIO) have already consolidated their position in the market and muscling a share from these early adaptors may prove to be an uphill task for the legacy automaker.

NIO Inc. (NIO), closed Thursday's trading session at $14.77, off by 7.9177%, on 67,739,039 volume. The average volume for the last 3 months is 31.875M and the stock's 52-week low/high is $11.67/$44.27.

The QualityStocks Company Corner

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced the expansion of its product portfolio pipeline to serve the growing cardiac device wearable technology market by bringing clinically relevant diagnostic information to patients and clinicians. According to the update, the product pipeline advancement allows for the addition of arrhythmia detection capabilities to address the multibillion global market for atrial fibrillation and other arrhythmia monitoring. “Adding smartwatch connectivity to our platform is a significant development as it extends our portfolio by enabling 24/7 heart monitoring capability,” said Branislav Vajdic, PhD, HeartBeam founder and CEO. “Coupled with our breakthrough AIMIGo solution, we believe the overall HeartBeam system will bring a new and much higher level of diagnostic capability to cardiac patients. We continue to make steady progress in realizing our vision of bringing comprehensive cardiac care to patients anytime, anywhere.” To view the full press release, visit https://ibn.fm/aOxz6

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Thursday's trading session at $5.73, up 26.4901%, on 31,874,596 volume. The average volume for the last 3 months is 6,571 and the stock's 52-week low/high is $1.12/$6.74.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. “Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes, and dementia, among others. These efforts have yielded 27 granted patents around the world since 2014, with approximately 50 additional patents pending. It also has national filings in over 40 jurisdictions with the highest commercial potential, reflecting the company’s commitment to creating shareholder value and pushing its technology further into the market,” a recent article reads. “Through its four subsidiary companies, Lexaria has explored various sectors such as cannabidiol for hypertension, oral nicotine for reduced risk, and antiviral drugs for COVID-19 and other infectious diseases. The progress so far has also allowed Lexaria to sub-license its DehydraTECH(TM) worldwide for delivering fat-soluble active molecules and drugs, thereby increasing the number of people who benefit from this technology and the number of lives impacted by it… As it pushes for the approval of additional patents and the licensing of its technology, the company looks to grow its market share significantly while redefining drug delivery platforms.” To view the full article, visit https://ibn.fm/9miut

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $2.5, up 3.3058%, on 6,571 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.74/$.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora Growth Corp. (NASDAQ: FLGC) , throughout 2022, has been implementing its hiring strategy that has seen the appointment of several key individuals whose proven talents and productivity are critical to the company’s goal of delivering the most compelling customer experiences. “Flora Growth ushered in the new year with the appointment of Tim Leslie as chairman of its newly formed advisory board. It would later bring Derek Pedro, an industry-leading cannabis genetics and cultivation expert, on board as an advisor and named Vessel founder James Choe as chief strategy officer. In February 2022, Flora Growth announced the appointment of Jessie Casner as the company’s chief marketing officer and, in March, made two changes to its board. Then, in early June, Flora announced the appointment of Holly Bell as the new vice president of regulatory affairs…. So far, all of Flora Growth’s appointments have been geared toward strengthening its human resources and moving the company closer to its objectives. Its latest appointment of Elshad Garayev is no different. Mr. Garayev was brought on board to serve as CFO,” a recent article reads. “Mr. Garayev adds to a growing list of competent, experienced and capable individuals ready to take on the challenges ahead and elevate Flora Growth to another level of performance.” To view the full article, visit https://cnw.fm/iROhg

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Thursday's trading session at $0.78, up 16.4179%, on 1,953,617 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.586/$6.29.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today provided an update on its intellectual property (“IP”) progress in support of its research and development strategy. According to the update, Cybin continues to prioritize the development of in-house IP and licensing opportunities that support its active development programs and future novel drug candidates. The company has more than 20 active patent filings — 14 of which were filed this year alone — across six patent families. Additionally, Cybin has entered into multiple licensing agreements that provide additional access to IP from over 15 more patents or patent applications. Collectively, through a combination of internal filings and licensing arrangements, the company has access to more than 35 patents and applications. “Securing and maintaining a robust IP portfolio is an important component of our approach to successful drug development,” said Cybin Chief Executive Officer Doug Drysdale. “We are focused on adding targeted IP that we believe complements our research and development strategy, supports our position as an innovator in the psychedelic therapeutics space, and will continue to build shareholder value.” To view the full press release, visit https://ibn.fm/P6SWt

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Thursday's trading session at $0.6399, up 1.4105%, on 660,474 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3903/$2.355.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs

With concussion representing a high unmet need as there is currently no FDA-approved drug, Odyssey is developing a drug formulation, PRV-002, to be administered to concussed patients; the drug candidate is currently undergoing clinical evaluation

In a recent announcement, the company reported the successful completion of its Phase I clinical trial, which showed that the drug was safe and well tolerated

Odyssey is looking to present the findings of the Phase I study to the FDA and is also preparing for the planned Phase II trial

A soft and squishy organ that can be deformed with a simple touch, the human brain is extremely sensitive. And although it is encased in a sturdy skull and surrounded by a cushioning fluid that collectively work to protect it from the external environment and forces that could easily wreak havoc, it is still vulnerable to extremities. In fact, blows, jolts, violent shaking, or rapid decelerations as a result of an accident, for example, can and do override these protections, leading to a mild form of brain injury called mTBI or concussion or mTBI, an area of interest for medical company Odyssey Health (OTC: ODYY) . Odyssey Health (OTC: ODYY) , a company focused on developing unique, life-saving medical products, today provided a recap of its concussion drug development program. Concussions affect millions worldwide and represent an ‘unmet’ medical need, while repetitive concussions can increase the risk of developing chronic traumatic encephalopathy (“CTE”) and other neuropsychiatric disorders. Since acquisition of the intellectual property and all rights to the drug on March 1, 2021, Odyssey has made significant progress in its development program. Among many key milestones provided in the update, the company announced successful completion of the pre-clinical toxicology program and IND enabling safety studies for a phase I human trial. Odyssey is currently communicating with the U.S. Food and Drug Administration (“FDA”) to present findings from the phase I trial. The company is also identifying phase II trial sites and creating study design in collaboration with medical leadership and advisors. To view the full press release, visit https://ibn.fm/Np2DP .

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Thursday's trading session at $0.28, up 11.8881%, on 101,200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.11/$0.64.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

With abortion bans going into effect in different regions in the country, oncologists are trying to gauge how these new laws will impact treatment options for cancer patients who are pregnant. Cancer coincides with about one in every thousand pregnancies, with cancers such as leukemias, lymphomas, cervical cancer, melanoma and breast cancer being the most common. While the new abortion restrictions stipulate that exceptions based on life-threatening physical conditions and medical emergencies will be permitted, cancer physicians fear misinterpretation, noting that the legal terms remain unclear. Given that most cancer treatments and medications are toxic to growing fetuses and may cause birth defects, cancer physicians are at a loss. It doesn’t help that during pregnancy, supercharged hormones fuel the growth of the cancer, which puts patients at an even greater risk. For instance, patients with brain cancer are usually advised to abort if a pregnancy may delay or limit radiation, surgery or other treatments. A research overview from Current Oncology Reports highlights that pregnant cancer patients need to be treated in a way that is similar to nonpregnant patients when possible. Physicians advise patients with breast cancer to undergo surgery early on as part of their therapy regimen, introducing chemotherapy later. Experts usually recommend avoiding most chemotherapy medications during the first trimester of pregnancy and radiation throughout the pregnancy period. As safer treatments for different oncology indications are brought onto the market by companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) , expectant mothers could have wider room for choice outside the possibility of aborting their unborn babies so that cancer therapy can be administered.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $0.1878, up 2.9605%, on 96,457 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1662/$1.55.

Recent News

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

Sugarmade (OTC: SGMD) , an emerging leader in the licensed cannabis sector, recently signed a management services agreement (“MSA”), marking a key milestone as the company actively strengthens its position in the California cannabis space. “SGMD signed the MSA through its subsidiary, SugarRush, which entered into the agreement with Canndis Inc., a California cannabis micro license holder. Canndis holds a license that covers delivery, manufacturing, distribution, and cultivation rights, and the agreement will enable Sugarmade to expand its manufacturing and distribution footprint,” a recent article reads. “Sugarmade is anticipating harvesting [its first crop], an accomplishment made possible through the company’s acquisition of a minority stake in RMI Ventures (d/b/a Jerusalem Grade Farm)… The MSA calls for Sugarmade to assume management responsibilities and operational control over manufacturing and distribution of cultivated cannabis produced at Jerusalem Grade Farm. The agreement also expands Sugarmade’s manufacturing and distribution footprint and will provide for the establishment of a new strategically located manufacturing and distribution hub near Palm Springs, California, as Sugarmade brings that harvest to market.” To view the full article, visit https://cnw.fm/V5ADq

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

  • NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
  • BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.

Management

Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Thursday's trading session at $0.0003, up 20%, on 83,701,096 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0002/$0.0019.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

  • REZYFi, Inc. is a real estate-oriented mortgage company servicing the needs of both traditional and non-traditional consumers and businesses
  • The company operates through its two subsidiaries, REZYFi Lending, which is now focused on cannabis commercial real estate lending, and ResMac, Inc., a traditional mortgage origination, correspondent, and servicing business
  • REZYFi seeks to provide access to financial services to the cannabis industry, which is still largely underserved because large financial companies have continuously shied away due to the illegality of cannabis at the federal level
  • The US cannabis industry is expected to generate $52.6 billion in sales by 2026, up from an estimated $33 billion in 2022, figures that make it possibly the largest underbanked industry in the country

As of May 2022, 19 states, the District of Columbia, and two US territories – Guam and the Northern Mariana Islands – had legalized the recreational use of marijuana among adults, according to the National Conference of State Legislatures ( https://ibn.fm/SbcVu ). But federally, the possession and use of cannabis are illegal, as per the Controlled Substances Act of 1970 (“CSA”). And as a Financial Times (“FT”) article reports, cannabis companies had long been caught in the gap between state and federal law. “With top US banks such as JPMorgan Chase (NYSE: JPM) and Wells Fargo (NYSE: WFC) and payment companies including Visa (NYSE: V) and Mastercard (NYSE: MA) adhering to federal law, they have opted out of serving cannabis companies,” the FT article reads ( https://ibn.fm/FSpMX ). This had long starved cannabis companies of the ability to transact electronically, take out loans, and make deposits. However, the situation is changing for the better thanks to financial services companies like REZYFi that have emerged to cater to the cannabis industry.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.

Operations

REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.


Recent News

chart

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

Hurricane Ian is the latest reminder that 83% of all major power outages are weather related

GeoSolar Technologies SmartGreen(TM) homes include rooftop solar panels, battery systems, geothermal loops and electric air pump, premium insulation and more

Installing a SmartGreen(TM) system reduces emissions by 8 tons annually and can eliminate energy-related utility bills

Devastating weather events like Hurricane Ian regularly leave millions of people throughout the path of the storm without power. In fact, it weather is nearly always responsible for major power outages, the culprit in 83% between 2000 and 2021, according to Climate Central . This begs the question of what can be done to help develop resilience? An answer: renewable energy and all-home solutions like that of GeoSolar Technologies (“GST”).

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.

 

The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.

GeoSolarPlus®

The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.


Recent News

chart

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

EverGen (TSX.V: EVGN) (OTCQB: EVGIF) today announced its appointment announce the appointment of Sean Hennessy as chief financial officer, effective immediately. Sean previously held the position of vice president, finance and controller. “We are excited to add Sean to our executive team,” said Chase Edgelow, CEO of EverGen. “Sean brings extensive financial and strategic experience to EverGen. He has been deeply involved with EverGen since the beginning of this year and this move is a seamless transition to bring our CFO role in-house. We would like to thank Natasha Monk, our interim CFO and partner at Affirm LLP, who will continue to work with and support EverGen as the company’s primary accounting and tax advisor.” To view the full press release, visit https://ibn.fm/Ebkoy

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Thursday's trading session at $2, even for the day. The average volume for the last 3 months is 2,000 and the stock's 52-week low/high is $2.00/$4.21.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

After decades of prohibition, 37 states now allow their citizens to use cannabis for medical purposes. Research has found that the plant is capable of alleviating a variety of medical conditions with few side effects. As a result, millions of people across America have begun using cannabis to treat conditions such as anxiety, insomnia and chronic pain. The surge in cannabis popularity began as people became more aware of the risks associated with opioid use. Although opioids have proven to be instrumental in treating chronic pain conditions, their side effects can be quite severe, ranging from nausea, vomiting and constipation to physical dependence and addiction. The opioid crisis has taken hundreds of thousands of lives over the past two decades and cost the United States trillions of dollars. Consequently, patients are becoming wary of using opioids to alleviate pain, especially those who have witnessed or experienced side effects firsthand. Cannabis, which has similar pain relief effects without the severe side effects, has proven to be an attractive alternative. As the use of medical cannabis becomes widespread across the country, there is a chance that home-grow equipment such as the grow pods sold by Advanced Container Technologies Inc. (OTC: ACTX) will proliferate and fewer people will solely depend on store-bought marijuana products.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Thursday's trading session at $0.5, off by 8.7591%, on 6,199 volume. The average volume for the last 3 months is 6,199 and the stock's 52-week low/high is $0.2005/$1.87.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG) today announced the first national travel event of its wholly owned subsidiary HAPI TRAVEL DESTINATIONS (“Hapi Travel”), which offers a new approach to travel savings and a unique opportunity for additional income in the new gig economy. Tickets are available now for the event , slated to take place on Nov. 11 and 12, 2022, which is open to the public and will feature secrets and tips on taking advantage of the best prices for getaways, business travel, flights, hotels and more. “We are excited to host this event for our newly launched company and its amazing travel platform,” said John “JT” Thatch, SHRG CEO. “People are traveling again in record numbers and are looking for the best value when enjoying their vacations or long weekend getaways. Hapi Travel is a unique membership-based travel club designed for maximum savings on the most luxurious vacation getaways throughout the world.” To view the full press release, visit https://ibn.fm/CrTxd

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.